BioSig Technologies Inc (BSGM) Raised to “Hold” at Zacks Investment Research


BioSig Technologies Inc (NASDAQ:BSGM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “BioSig Technologies, Inc. is a medical device company which is engaged in developing technology platform to improve cardiac recording during electrophysiology studies and ablation procedures. BioSig Technologies, Inc. is headquartered in Minnesota. “
BioSig Technologies (NASDAQ:BSGM) traded down 2.53% during mid-day trading on Tuesday, reaching $1.54. 101,591 shares of the company were exchanged. BioSig Technologies has a 1-year low of $0.90 and a 1-year high of $2.20. The firm’s market capitalization is $31.53 million. The stock has a 50-day moving average of $1.36 and a 200 day moving average of $1.49.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

BioSig Technologies, Inc is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System.
Get a free copy of the Zacks research report on BioSig Technologies (BSGM)
For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioSig Technologies Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioSig Technologies Inc and related companies with’s FREE daily email newsletter.

Be the first to comment on "BioSig Technologies Inc (BSGM) Raised to “Hold” at Zacks Investment Research"

Leave a comment

Your email address will not be published.